Table 1.
Clinical and biochemical characteristics of study population according to group of treatment
| 25(OH)D group baseline (n = 26) | Placebo group baseline (n = 29) | |
|---|---|---|
| Age (years) | 57.4 ± 10.7 | 59.8 ± 9.1 |
| Gender (%M) | 70 % | 60 % |
| T2D duration (years) | 5.9 ± 5.8 | 6.3 ± 5.4 |
| 25(OH)D (nmol/L) | 48.15 ± 23.7 | 40.14 ± 23.9 |
| HFF (%) | 7.6 ± 5.7 | 6.8 ± 5.5 |
| BMI (kg/m2) | 29.3 ± 4.4 | 30.8 ± 4.5 |
| Waist circumference (cm) | 100.6 ± 15.2 | 105.2 ± 12.1 |
| SBP (mmHg) | 129.7 ± 16.8 | 132.2 ± 17.4 |
| DBP (mmHg) | 79.2 ± 8.9 | 82.7 ± 10.7 |
| Total cholesterol (mg/dL) | 167.7 ± 37.5 | 181.6 ± 39.5 |
| HDL-C (mg/dL) | 50.3 ± 16.4 | 49.3 ± 13.2 |
| LDL-C (mg/dL) | 93 ± 33.6 | 105.2 ± 34.5 |
| Triglycerides (mg/dL) | 131.5 ± 72.7 | 133.5 ± 43.8 |
| FBG (mg/dL) | 125.3 ± 36.8 | 135.1 ± 39.9 |
| HbA1c (%/mmol/mol) | 6.36 ± 0.9/46 ± 8 | 6.6 ± 1/48 ± 8 |
| AST (IU/L) | 24.12 ± 11.8 | 23.8 ± 14.6 |
| ALT (IU/L) | 31.7 ± 17.1 | 32.4 ± 26.2 |
| γ-GT (IU/L) | 45.3 ± 56.4 | 35.8 ± 33.3 |
| AST/ALT | 0.84 ± 0.3 | 0.83 ± 0.26 |
| FFAs (μmol/L) | 464.6 ± 224.5 | 519.9 ± 218.4 |
| CK18-M30 (mIU/mL) | 212.2 ± 128.2 | 212.1 ± 155.2 |
| P3NP (pg/mL) | 1210.5 ± 1028.6 | 833.9 ± 955.4 |
| FBI (μU/L) | 12 ± 5.1 | 12.7 ± 5.8 |
| FLI | 56.82 ± 26.4 | 67.7 ± 23.7 |
| HOMA-IR | 3.57 ± 1.9 | 3.87 ± 1.6 |
| HOMA-β% | 89.6 ± 63 | 83.8 ± 63.7 |
| QUICKI | 0.33 ± 0.03 | 0.32 ± 0.02 |
| ADIPO-IR | 5.1 ± 3.5 | 6.3 ± 4.7 |
| CRP (mg/dL) | 3.1 ± 3.1 | 3.6 ± 4.8 |
| Adiponectin (ng/mL) | 6.37 ± 3.7 | 6.4 ± 3.2 |
| VAT area (cm2) | 195.9 ± 78.2 | 191.4 ± 65.9 |
| SAT area (cm2) | 229 ± 28.4 | 258.01 ± 123.9 |
| VAT/SAT ratio | 1.07 ± 0.6 | 1.07 ± 0.62 |
| FMD (%) | 5.04 ± 4.5 | 4.5 ± 3.6 |
| ABI | 1.14 ± 0.19 | 1.1 ± 0.13 |
| IMT (mm) | 0.91 ± 0.25 | 0.87 ± 0.19 |
Data are presented as mean ± SD, unless indicated otherwise
T2D type 2 diabetes, HFF hepatic fat fraction, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, FBI fasting blood insulin, FLI fatty liver index, CRP C reactive protein, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, FMD flow-mediated dilatation, ABI ankle-brachial index, IMT intima-media thickness